Founded in 2018, the Lund- based Digital therapeutics company, Paindrainer, recently announced that it has successfully completed a share issue of 10 Million SEK (€ 880.000).
The funding boost will enable the company to launch their innovative digital self-management tool for chronic pain patients without drugs. In addition, it will enable the company to speed up the incorporation of wearables into the product, resulting in greater patient convenience, engagement, and accuracy of input data.
“Having achieved outstanding clinical evidence, commercialization of Paindrainer is our top priority in 2023. There is a high demand for drug-free remote therapeutic monitoring products in the USA and it provides a great opportunity to enter the US market and partner with clinics directly.”
says Erik Frick, CEO Paindrainer
Paindrainer is blazing a trail in the healthcare industry by harnessing the power of digital therapeutics (DTx). Their flagship product, the Paindrainer App, is a groundbreaking, evidence-based digital tool that employs an advanced Artificial Neural Network (ANN) to provide a fully personalised and patient-centered approach to chronic pain management.
